Genmab Announces Positive Results in the Phase II GRIFFIN Study in Newly Diagnosed Patients with Daratumumab-treated Multiple Myeloma Patients Eligible for Transplantation in Combination with Lenalidomide, Bortezomib and Dexamethasone

[ad_1] Business Announcement The main data from the randomized phase II study GRIFFIN in newly diagnosed, treatment-eligible multiple myeloma patients treated with daratumumab in combination with lenalidomide, bortezomib, and dexamethasone have shown …

Read More »